Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector

F Dupont1, B Avalosse, A Karim

  • 1Laboratoire d'Investigation Clinique et d'Oncologie Expérimentale, Unité d'Oncologie Moléculaire, Belgium.

Gene Therapy
|May 24, 2000
PubMed

Insights

Minute virus of mice (MVMp) vectors show selective gene expression and killing of tumor cells, sparing normal cells. This suggests MVMp

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy vectors
  • Molecular virology

Background:

  • Minute virus of mice (MVMp) is a parvovirus with potential for targeted gene delivery.
  • Developing selective cancer therapies remains a critical challenge in oncology.

Purpose of the Study:

  • To evaluate the potential of MVMp-based vectors for selective anticancer gene therapy.
  • To assess the efficiency of MVMp-mediated gene transduction and cytotoxicity in various tumor and normal cell types.

Main Methods:

  • Recombinant MVMp vectors expressing reporter genes (CAT, GFP) and a cytotoxic gene (HSV-TK) were constructed.
  • Infection of normal and tumor-derived cell lines (melanocytes, breast cancer, glioma, neurons, fibroblasts) with MVMp vectors.
  • Assessment of reporter gene expression, gene transduction efficiency (flow cytometry), and ganciclovir-mediated cytotoxicity.

Main Results:

  • MVMp vectors demonstrated significantly higher reporter gene expression and gene transduction in tumor cells compared to normal cells.
  • Recombinant MVMp expressing herpes simplex virus thymidine kinase (HSV-TK) efficiently killed most tested tumor cells in the presence of ganciclovir.
  • Breast tumor cells showed resistance to ganciclovir-mediated killing, potentially due to a lack of bystander effect.

Conclusions:

  • MVMp-based vectors exhibit selective targeting of tumor cells, with efficient gene delivery and oncolytic potential.
  • These vectors hold promise for in vivo delivery of cytotoxic effector genes in anticancer gene therapy.
  • Further investigation is needed to address resistance mechanisms, such as in breast tumor cells.

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...